Kura Oncology, Inc. - Common Stock (NQ:KURA)

10.62 -0.03 (-0.28%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kura Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Kura Oncology Stock Is Moving Higher Tuesday Morning ↗

January 24, 2023

Kura Oncology Inc (NASDAQ: KURA) shares are trading higher Tuesday after the company announced the FDA clearance of its Inve

Via Benzinga

Cramer Is Holding This Biotech Stock ↗

January 12, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding Biomarin Pharmaceutical Inc (NASDAQ: BMRN).

Via Benzinga

Kura Oncology Shares Fall After Updated Ziftomenib Data At ASH Meeting ↗

December 12, 2022

Via Benzinga

RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗

December 12, 2022

U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 22, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Kura Oncology Reports Preliminary Proof Of Mechanism Data From Early-Stage In Head & Neck Cancer ↗

October 26, 2022

Via Benzinga

Read Why Did Credit Suisse Raise Price Target On Kura Oncology ↗

July 13, 2022

Via Benzinga

Preview: Kura Oncology's Earnings ↗

November 02, 2022

Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Kura Oncology...

Via Benzinga

Kura Oncology Stock Shows Improved Relative Strength; Still Shy Of Benchmark ↗

October 14, 2022

In a welcome move, Kura Oncology stock saw its Relative Strength Rating improve from 69 to 75 on Wednesday.

Via Investor's Business Daily

Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session ↗

September 30, 2022

Gainers

Via Benzinga

Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday ↗

September 30, 2022

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

August 08, 2022

On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier.

Via Investor's Business Daily

7 Cheap Biotech Stocks to Buy Now ↗

August 03, 2022

These cheap biotech stocks to buy offer investors a way to get ready for the inevitable comeback in the biopharmaceutical sector.

Via InvestorPlace

Earnings Preview: Kura Oncology ↗

August 02, 2022

Kura Oncology (NASDAQ:KURA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Kura...

Via Benzinga

Kura Oncology Stock Scores Rising Relative Strength ↗

June 30, 2022

On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022 ↗

July 12, 2022

Upgrades

Via Benzinga

PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst ↗

May 25, 2022

Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than...

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Kura Oncology, Inc. (NASDAQ:KURA) Investor Notice: Investigation over Potential Wrongdoing ↗

March 04, 2022

San Diego, CA -- (SBWIRE) -- 03/04/2022 -- Certain directors of Kura Oncology, Inc are under investigation over potential breaches of fiduciary duties.

Via SBWire

Kura Oncology: Q4 Earnings Insights ↗

February 24, 2022

Kura Oncology (NASDAQ:KURA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022 ↗

February 15, 2022

Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the first quarter, compared to $0.00 in the year-...

Via Benzinga

The Daily Biotech Pulse: Kura Lifts Clinical Hold On Blood Cancer Trial, Intuitive Surgical Earnings, Sorrento's Omicron Antibody Treatment Effective ↗

January 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kura Announces Lifting Of Clinical Hold On Phase 1 Blood Cancer Study Kura...

Via Benzinga

Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer

February 02, 2022

Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...

Via FinancialNewsMedia

FDA Lifts Partial Hold On Kura Oncology's Early-Stage Leukemia Trial ↗

January 21, 2022

The FDA has lifted the partial clinical hold on Kura Oncology Inc (NASDAQ: KURA) KOMET-001 Phase 1b study of KO-539 in patients with relapsed or refractory...

Via Benzinga

NASDAQ:KURA Investor Notice: Investigation over Possible Securities Laws Violations by Kura Oncology, Inc. ↗

December 09, 2021

San Diego, CA -- (SBWIRE) -- 12/09/2021 -- Kura Oncology, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More ↗

December 06, 2021

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

November 24, 2021

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target. Longeveron Inc...

Via Benzinga

68 Biggest Movers From Wednesday ↗

November 26, 2021

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share. Longeveron Inc. (...

Via Benzinga

Topics Initial Public Offering

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.